Protocol No
HJKC3-0003
Phase
II
Summary
The purpose of this study is to determine if adding asciminib to imatinib prior to a second attempt at stopping imatinib will lead to prolonged treatment free remission.
Description
Treatment Free Remission After Asciminib plus Imatinib in CP-CML
Participating Institutions
Karmanos Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Utah Huntsman Cancer Institute
Froedtert Hospital
Moorland Reserve Health Center
Memorial Sloan Kettering Cancer Center - Bergen
Lawrence And Idell Weisberg Cancer Treatment Center
Memorial Sloan Kettering Cancer Center - Monmouth
Status
OPEN TO ACCRUAL
Categories
ClinicalTrials.gov